-
公开(公告)号：US20120135923A1
公开(公告)日：2012-05-31
申请号：US13388387
申请日：2010-07-30
Applicant: Heather A. Halem , Michael DeWitt Culler
Inventor： Heather A. Halem , Michael DeWitt Culler
CPC classification number: A61K38/33 , A61K38/34 , C07K14/665
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.
Abstract translation: 本发明涉及黑皮质素受体，特别是melancortin-4受体的肽配体，因此可用于治疗血脂异常和相关并发症如酒精和非酒精性脂肪性肝病。
-
2.发明申请
公开(公告)号：US20110183416A1
公开(公告)日：2011-07-28
申请号：US11810268
申请日：2007-06-05
Applicant: Ettore Ciro Degli Uberti , Maria Chiara Zatelli , Michael Dewitt Culler , David H. Coy
Abstract: The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. A preferred selective somatostatin receptor type-2 (SSTR-2) agonist cyclo[Tic-Tyr-D-Trp-Lys-Abu-Phe] is also disclosed.
Abstract translation: 本发明涉及一种降低髓样甲状腺癌细胞增殖速率的方法，其包括使髓样甲状腺癌细胞与一种或多种SSTR2激动剂接触。 还公开了优选的选择性促生长素抑制素受体2型（SSTR-2）激动剂环[Tic-Tyr-D-Trp-Lys-Abu-Phe]。
-
公开(公告)号：US20100311647A1
公开(公告)日：2010-12-09
申请号：US12740917
申请日：2008-11-05
Applicant: Heather A. Halem , Michael Dewitt Culler , Andrew A. Butler
Inventor： Heather A. Halem , Michael Dewitt Culler , Andrew A. Butler
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
Abstract translation: 本发明涉及黑皮质素受体，特别是黑皮质素-4受体的肽配体，因此可用于治疗对该受体的活化反应的病症，例如胰岛素抵抗。
-
公开(公告)号：US09155777B2
公开(公告)日：2015-10-13
申请号：US12740917
申请日：2008-11-05
Applicant: Heather A. Halem , Michael Dewitt Culler , Andrew A. Butler
Inventor： Heather A. Halem , Michael Dewitt Culler , Andrew A. Butler
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
Abstract translation: 本发明涉及黑皮质素受体，特别是黑皮质素-4受体的肽配体，因此可用于治疗对该受体的活化反应的病症，例如胰岛素抵抗。
-
公开(公告)号：US08822442B2
公开(公告)日：2014-09-02
申请号：US11262403
申请日：2005-10-28
Applicant: Zheng Xin Dong , Michael Dewitt Culler , Yeelena Shen
Inventor： Zheng Xin Dong , Michael Dewitt Culler , Yeelena Shen
IPC: A01N43/00 , A01N43/40 , A01N43/42 , A01N43/64 , A01N43/36 , A61K31/33 , A61K38/00 , A61K38/31 , A61K38/12 , A61K38/08 , A61K31/44 , A61K31/41 , A61K31/40 , A61P5/02 , A61P35/00 , A61P35/04 , C07K14/655 , C07K5/00 , C07K16/00 , C07K17/00
CPC classification number: C07K14/6555 , A61K38/00 , C07D265/34 , C07D471/06 , C07D491/056 , C07D513/04 , Y02A50/475
Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
Abstract translation: 本发明的特征在于生长抑素 - 多巴胺嵌合类似物和与其用于治疗瘤形成，肢端肥大症和其它病症的治疗用途有关的方法。
-
6.发明申请USE OF A GHRELIN AGONIST TO IMPROVE THE CATABOLIC EFFECTS OF GLUCOCORTICOID TREATMENT 有权使用GHRELIN AGONIST来提高葡萄糖激素治疗的临床效果
公开(公告)号：US20120129767A1
公开(公告)日：2012-05-24
申请号：US13287211
申请日：2011-11-02
Applicant: Giovanni Tulipano , Andrea Giustina , Zheng Xin Dong , Michael DeWitt Culler
Inventor： Giovanni Tulipano , Andrea Giustina , Zheng Xin Dong , Michael DeWitt Culler
CPC classification number: A61K38/25
Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.
Abstract translation: 通过给予例如[Aib2，Glu3（NH-hexyl）] hGhrelin（1-28）-NH2的生长素释放肽或生长素释放肽类似物抑制糖皮质激素（特别是地塞米松）抑制生长激素分泌的作用的方法和药物组合物 （SEQ ID NO：2）或其他合适的生长素释放肽激动剂，以抵消所述地塞米松和其他天然糖皮质激素的分解代谢作用。
-
公开(公告)号：US20090156483A1
公开(公告)日：2009-06-18
申请号：US12079885
申请日：2008-03-28
Applicant: Zheng Xin Dong , Michael DeWitt Culler , Yeelana Shen , Jeanne Mary Comstock
Inventor： Zheng Xin Dong , Michael DeWitt Culler , Yeelana Shen , Jeanne Mary Comstock
CPC classification number: C07K14/60 , A61K38/00 , G01N2500/00 , Y02A50/463 , Y02A50/475
Abstract: The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: (R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13- A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25- A-26-A27-A28-R1 wherein the definitions of A1 to A28 and R1 to R3 are provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
Abstract translation: 本发明包括如下所述的式（I）或（II）的肽基类似物：
（R2R3）-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13 - / row> A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25 - A-26-A27-A28-R1 在式（I）和（II）中的每一个的说明书中提供了A1至A28和R1至R3的定义，其药学上可接受的盐和包含有效量的 具有激动剂或拮抗性生长素释放肽活性的式（I）化合物及其治疗和非治疗用途。 -
公开(公告)号：US07517853B2
公开(公告)日：2009-04-14
申请号：US10553014
申请日：2004-04-08
Applicant: Zheng Xin Dong , Michael DeWitt Culler , Yeelena Shen
Inventor： Zheng Xin Dong , Michael DeWitt Culler , Yeelena Shen
IPC: A61K38/12
CPC classification number: C07K14/6555 , A61K38/00 , C07D265/34 , C07D471/06 , C07D491/056 , C07D513/04 , Y02A50/475
Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
Abstract translation: 本发明的特征在于生长抑素 - 多巴胺嵌合类似物和与其用于治疗瘤形成，肢端肥大症和其它病症的治疗用途有关的方法。
-
9.发明授权Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue 有权使用生长素释放肽类似物抑制炎症和炎症前细胞因子/趋化因子表达的方法
公开(公告)号：US08871706B2
公开(公告)日：2014-10-28
申请号：US12672681
申请日：2008-08-07
Applicant: Zheng Xin Dong , Michael DeWitt Culler , Rakesh Datta , John E. Taylor
Inventor： Zheng Xin Dong , Michael DeWitt Culler , Rakesh Datta , John E. Taylor
CPC classification number: A61K38/22 , A61K38/05 , A61K38/06 , A61K38/25 , C07K7/06 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/463 , Y02A50/475 , Y02A50/481 , Y02A50/484
Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogous of native hGhrelin.
Abstract translation: 本发明提供了一种在需要治疗这些病症的受试者中通过施用天然的选择类似物来改善炎症，抑制促炎细胞因子和/或趋化因子表达并且治疗与发作炎症相关的各种疾病和/或病症的方法 hGhrelin。
-
公开(公告)号：US08236762B2
公开(公告)日：2012-08-07
申请号：US12311961
申请日：2007-10-17
Applicant: Zheng Xin Dong , Yeelana Shen , Michael DeWitt Culler , Christophe Alain Thurieau , Jundong Zhang , Sun Hyuk Kim
Inventor： Zheng Xin Dong , Yeelana Shen , Michael DeWitt Culler , Christophe Alain Thurieau , Jundong Zhang , Sun Hyuk Kim
CPC classification number: C07K14/655 , A61K38/00 , C07D491/22
Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.
Abstract translation: 本发明的特征在于靶向的细胞毒性化合物和与其用于治疗瘤形成和其他病症的治疗用途有关的方法。
-
